RCS - Shield Therapeutics - Shield Wins Gold at Titan Branding Awards

Shield TherapeuticsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251211:nRSK0971La&default-theme=true

RNS Number : 0971L  Shield Therapeutics PLC  11 December 2025

 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Shield Therapeutics Wins Gold at Titan Branding Awards for ACCRUFeR's Brand
Transformation

 

London, UK, December 11, 2025: Shield Therapeutics plc (LSE: STX), a
commercial-stage pharmaceutical company specialising in iron deficiency
announces that it has been awarded Gold at the 2025 Titan Brand Awards for
Best Rebranding Effort, Best Healthcare Rebranding for ACCRUFeR®.

 

The Titan Brand Awards represent international recognition for outstanding
achievements in branding, highlighting effective brand strategies, creative
thinking, and strong communication that help organisations distinguish
themselves in competitive markets. This prestigious recognition elevates
ACCRUFeR® into the ranks of globally respected brands, both within the
pharmaceutical industry and across broader sectors, underscoring its position
as a trusted name on the world stage.

 

Andy Hurley, CCO at Shield, commented: "We are proud to receive the "Best
Rebranding Effort" award for ACCRUFeR®, recognising the team's dedication to
transforming ACCRUFeR®, into a highly differentiated, patient-focused brand.
These efforts have enabled us to highlight the real impact of ACCRUFeR®, in
the vastly prevalent ID/IDA market which is a serious condition with a
significant unmet need for patients and HCPs. Our refreshed brand is
contemporary, engaging, and underscores our commitment to improving lives, and
has enabled ACCRUFeR® to be the #1 branded prescription oral iron in the US
ID/IDA market. This is the first step in our digital marketing initiative
driving growth of ACCRUFeR®."

 

 

For further information please contact:

 

 Shield Therapeutics plc                     www.shieldtherapeutics.com (http://www.shieldtherapeutics.com)
 Anders Lundstrom, CEO                       +44 (0) 191 511 8500

 Santosh Shanbhag, CFO                       Investorrelations@shieldtx.com

 Stephanie Hicks, Investor Relations
                                             +1 804 317 3352

 Marketing Agency                            agray@reingold.com

 Reingold, Inc.

 Alexandra Gray, Public Relations Director

About Iron Deficiency and ACCRUFeR®/FeRACCRU®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health
problems for adults of all ages, across multiple therapeutic areas. Together,
ID and ID with anemia (IDA) affect about 20 million people in the US and
represent a $2.3B market opportunity. As the first and only FDA approved oral
iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet
medical need for both physicians and patients and is now the #1 branded
prescription oral iron the market today (*data source - IQVIA Xponent
PlanTrak).

 

ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral
therapy for adults with ID/IDA. The drug has a novel mechanism of absorption
compared to other oral iron therapies and has been shown to be an efficacious
and well-tolerated therapy in a range of clinical trials. More information
about ACCRUFeR®/FeRACCRU®, including the product label, can be found at:
www.accrufer.com (http://www.accrufer.com) and www.feraccru.com
(http://www.feraccru.com) .

 

 

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company that delivers
ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated
pharmaceutical product, to address a significant unmet need for patients
suffering from iron deficiency, with or without anemia. The Company has
launched ACCRUFeR® in the U.S. with an exclusive, multi-year collaboration
agreement with Viatris. Outside of the U.S., the Company has licensed the
rights to five specialty pharmaceutical companies. FeRACCRU® is
commercialised in the UK and European Union by Norgine B.V., which also has
marketing rights in Australia and New Zealand. FeRACCRU® is also
commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an
exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd.,
for the development and commercialisation of ACCRUFeR®/FeRACCRU® in China,
Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of
Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc.
for Japan.

 

ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.

ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRATMBMTMTBBTBA



            Copyright 2019 Regulatory News Service, all rights reserved